Comprehensive review on leucine-rich pentatricopeptide repeat-containing protein (LRPPRC, PPR protein): A burgeoning target for cancer therapy
View abstract on PubMed
Summary
This summary is machine-generated.Leucine-rich pentatricopeptide repeat-containing (LRPPRC) protein is crucial in cell functions and its elevated expression is linked to poor cancer prognosis. Targeting LRPPRC shows promise for cancer therapy and as a biomarker.
Area Of Science
- Molecular Biology
- Genetics
- Cancer Research
Background
- Leucine-rich pentatricopeptide repeat-containing (LRPPRC) protein is encoded by the LRPPRC gene, implicated in Leigh Syndrome French Canadian.
- LRPPRC regulates gene transcription and translation by interacting with DNA, RNA, and proteins, influencing cell fate.
- Emerging evidence highlights LRPPRC's significant role in human diseases, especially in recent cancer research.
Purpose Of The Study
- To review the structure, function, molecular mechanisms, and inhibitors of LRPPRC.
- To consolidate current understanding of LRPPRC's involvement in cancer.
- To evaluate LRPPRC as a potential therapeutic target and biomarker in oncology.
Main Methods
- Literature review focusing on LRPPRC's role in cellular processes and disease.
- Analysis of LRPPRC expression patterns in various cancer types.
- Examination of LRPPRC's impact on cancer hallmarks like signal transduction, metabolism, and immune regulation.
Main Results
- LRPPRC expression is elevated in most cancer types.
- High LRPPRC expression correlates with poor prognosis in cancer patients.
- Targeting LRPPRC effectively suppresses tumor progression by modulating key cancer pathways.
Conclusions
- LRPPRC is a promising therapeutic target and biomarker in cancer research.
- Modulating LRPPRC function can impact cancer hallmarks, including metabolism and immune response.
- Further research is needed to fully elucidate LRPPRC's mechanisms and optimize therapeutic strategies.

